• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Profusa Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    9/16/25 5:20:25 PM ET
    $PFSA
    Medical/Dental Instruments
    Health Care
    Get the next $PFSA alert in real time by email
    false 0001859807 0001859807 2025-09-11 2025-09-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): September 11, 2025

     

    PROFUSA, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41177   86-3437271
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    626 Bancroft Way, Suite A

    Berkeley, CA 94710

    (Address of principal executive offices, including zip code)

     

    Registrant’s telephone number, including area code: (925) 997-6925

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   PFSA   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    On September 11, 2025, Profusa, Inc. (the “Company”) received a notice (the “MVLS Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon its review of the market value of listed securities (“MVLS”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from July 29, 2025 to September 10, 2025, the Company no longer meets Nasdaq Listing Rule 5450(b)(2)(A), which requires companies listed on the Nasdaq Global Market to maintain a minimum MVLS of $50,000,000.

     

    Pursuant to Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided a compliance period of 180 calendar days, or until March 10, 2026, to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A). If at any time during this compliance period, the Common Stock’s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with written confirmation of compliance and this matter will be closed, provided, however that Nasdaq may, in its discretion, require the Company to maintain the minimum MVLS for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.

     

    In the event the Company does not regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) prior to the expiration of the compliance period, the Company will receive written notification that the Company’s securities are subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel. Alternatively, the Company may consider applying to transfer the listing of the Company’s securities to the Nasdaq Capital Market, provided that the Company then satisfies the requirements for continued listing on that market.

      

    The Company is monitoring the MVLS of its listed securities and is considering available options to regain compliance with Nasdaq’s continued listing standards. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) or maintain compliance with other applicable Nasdaq listing requirements.

     

    On September 11, 2025, the Company received a second notice (the “Bid Price Notice”, and together with the MVLS Notice, the “Notices”) from Nasdaq notifying the Company that, based upon its review of the closing bid price of the Common Stock, from July 29, 2025 to September 10, 2025, the Company no longer meets Nasdaq Listing Rule 5450(a)(1), which requires companies listed on the Nasdaq Global Market to maintain a minimum bid price of $1.00 per share.

     

    Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a compliance period of 180 calendar days, or until March 10, 2026, to regain compliance with Nasdaq Listing Rule 5450(a)(1). If at any time during this compliance period, the Common Stock has a closing bid price bid price of at least $1.00 per share for a minimum of ten consecutive business days, Nasdaq will provide the Company with written confirmation of compliance and this matter will be closed, provided, however that Nasdaq may, in its discretion, require the Company to maintain the minimum bid price for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.

     

    In the event the Company does not regain compliance with Nasdaq Listing Rule 5450(a)(1) prior to the expiration of the compliance period, then Nasdaq may grant the Company a second 180 calendar day period to regain compliance, provided, among other things, the Company meets the continued listing requirement for market value of publicly-held shares and all other initial listing standards for The Nasdaq Global Market, other than the minimum bid price requirement, and notifies Nasdaq of its intent to cure the deficiency. If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Common Stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel.

     

    The Company is monitoring the minimum bid price of its listed securities and is considering available options to regain compliance with Nasdaq’s continued listing standards. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5450(a)(1) or maintain compliance with other applicable Nasdaq listing requirements.

     

    The Notices have no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Market, which will continue to trade under the symbol “PFSA”, subject to the Company’s continued compliance with Nasdaq’s other continued listing requirements.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: September 16, 2025 Profusa, Inc.
         
      By: /s/ Ben Hwang
      Name: Ben Hwang
      Title: Chief Executive Officer

     

    2

     

    Get the next $PFSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PFSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PFSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering

    After Reevaluating its Near-term Capital Needs Given the Recent Changes in its Projected 2026 Revenue and Mayo Collaboration, the Company Determined that a $15 Million Offering is Not Required to Achieve Near-term Revenue Projections BERKELEY, CA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces it has elected not to proceed with its public offering and intends to file a post-effective amendment with the U.S. Securities and Exchange Commission (the "SEC") for the Company's

    2/27/26 9:15:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance

    With strong underlying market demand, European distributor and expert physician customer purchase orders are being received by the Company as its 2026 revenue guidance range increases to $1.5 million - $3 million BERKELEY, Calif, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces it has received several purchase orders for the Lumee™ tissue oxygen monitoring system from its growing network of European distributors and expert physician customers.  With strong underlying market

    2/19/26 8:30:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

    Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new tethered continuous oxygen monitoring products for high impact clinical applications BERKELEY, Calif, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform seeking to enable the continuous monitoring of an individual's biochemistry, has entered into a know-how agreement with Mayo Clinic.  The collaboration entails investigation of high impact clinical applicatio

    2/12/26 4:30:00 PM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Knechtel Fred S. acquired 818,961 shares (SEC Form 4)

    4 - Profusa, Inc. (0001859807) (Issuer)

    2/2/26 6:40:58 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Large owner Northview Sponsor I, Llc disposed of 4,743,750 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Profusa, Inc. (0001859807) (Issuer)

    2/2/26 6:36:30 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Director O'Rourke Peter acquired 107,750 shares (SEC Form 4)

    4 - Profusa, Inc. (0001859807) (Issuer)

    1/30/26 9:50:38 PM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    SEC Filings

    View All

    SEC Form EFFECT filed by Profusa Inc.

    EFFECT - Profusa, Inc. (0001859807) (Filer)

    3/4/26 12:15:14 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    SEC Form POS AM filed by Profusa Inc.

    POS AM - Profusa, Inc. (0001859807) (Filer)

    3/2/26 9:10:43 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Profusa Inc.

    EFFECT - Profusa, Inc. (0001859807) (Filer)

    2/18/26 12:15:10 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    Leadership Updates

    Live Leadership Updates

    View All

    Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO

    Board addition served in the Trump Administration, overseeing 1,300 facilities serving more than 9 million veterans; New CFO has led finance and operations at companies including Northrop Grumman, Stanley Black & Decker, and DuPont Berkeley, Calif, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces two major leadership additions as of the close of the business combination with NorthView Acquisition Corp (NVAC).  Peter O'Rourke, former Acting U.S. Secretary of Veterans Affair

    8/19/25 8:15:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    Financials

    Live finance-specific insights

    View All

    Profusa Announces Third Quarter Business and Financial Highlights

    Recapitalization reduced net debt to $14 million as of October 31; achieved key milestones to deliver potential 2026 revenue target BERKELEY, Calif, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces financial results for the third quarter ended September 30, 2025, and provides business highlights. Ben Hwang, Ph.D., Profusa's Chairman and CEO, said, "It was an extremely busy four months for the team, and we are proud of our achievements in such a short period of time. In the third

    11/19/25 5:44:52 PM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Report Highlights Growth in AI Biomarker Monitoring as Industry Giant's GPUs Power Next-Gen Platform

    MarketNewsUpdates News Commentary NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The global Diagnostic Biomarker market is experiencing unprecedented growth and is projected to continue to see substantial growth in years to come. A recent report from the (NIH) National Library of Medicine discussed the AI-Assisted Biomarker, said that: "Recently, advancements in healthcare digitization and personalized treatments have led to groundbreaking developments. Utilization of AI and ML has the potential to enhance comprehension of disease onset and progression, potentially uncovering new disease subtypes, unveiling novel drug targets, advancing the field of precision medicine, propelling efforts towards d

    9/11/25 8:45:00 AM ET
    $APLD
    $NBIS
    $NVDA
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology